Abstract: Compositions for the treatment of wounds and/or scars are described herein. The compositions contain between 1 and up to 30% by weight, more preferably between 1 and 20%, most preferably between about 5 and 10% by weight particles, such as titanium dioxide or a similar material in a pharmaceutically acceptable base or carrier, such as petrolatum. The compositions are less greasy than petrolatum alone, and thus are more aesthetically pleasing. The compositions exhibit occlusive properties comparable to petrolatum. The compositions are absorbed into the skin, unlike petrolatum, and exhibit significant wound healing characteristics not observed with petrolatum alone. In one embodiment, the pharmaceutically acceptable base is petrolatum and the particles are titanium dioxide. The compositions can be used to treat complex, hard to heal wounds, such as diabetic ulcers; pressure sores, such as bed sores; lacerations; bite wounds; burns; penetrating wounds; surgical wounds, etc.

Abstract: A baby formula is provided having enzymes added to imitate the effect of those present in normal breast milk, aiding digestion of protein, carbohydrate (simple and complex sugars), and lipid. The enzymes are either of procaryotic or eucaryotic origin, isolated from fermentation broth or tissue, or expressed from recombinant gene sequences. The enzymes are provided in a form for addition to the formula prior to feeding the infant or at the time of feeding. In the preferred form, the enzymes are provided in a form that is stable to storage in the formula, but active when the formula reaches the portion of the gastrointestinal tract where the formula would normally be digested. In the most preferred embodiment, the enzymes are provided in a matrix with an enteric coating that releases the enzyme in the upper portion of the intestine. Depending on the formulation, proteases, carbohydrate degrading enzymes such as alpha-amylase, lactase, fructase, and sucrase, or lipases, are added to the formulation.

Abstract: A process is described for the preparation of a novel protein product of a highly purified antihemophlic factor (AHF) concentrate. The product is prepared by use of a semi-permeable membrane apparatus that desalts the plasma to between 45 to 80% of its salt content while constantly maintaining the plasma at substantially its original starting pH level. Under these conditions the AHF portion of the plasma will precipitate.